On October 16, the New York Post’s “Post Wanted” shopping section promoted Timeline’s $99 Mitopure gummies with a trial sponsored by Amazentis, which sells Timeline, and an unnamed customer’s ‘ten years younger’. Two halves, joined by a colon. The left half borrows a lab coat: “Study shows.” The right half borrows a mirror: “ten years younger.” The colon invites you to read the second as the result of the first. The Post’s own page keeps them apart: its third paragraph describes the study and speaks of mitophagy, the cell’s clearing of worn-out mitochondria; the skin line arrives in the eighth paragraph, from a customer introduced only as “one shared”. The study is real. It gave 88 untrained, overweight adults aged 40 to 64 in London, Ontario, 500mg or 1,000mg of Mitopure or a placebo daily for 4 months. It measured muscle, exercise and blood and muscle biomarkers, not skin. Hamstring strength rose 12% and 9.8%; the higher dose’s endurance gains were not statistically significant. Its sponsor was Amazentis, which sells Mitopure under Timeline. The release does not say the doses were gummies. The headline names none of this. The habit it rides: the title does the proving, so the word study stops you asking who paid and what was measured. The device in the wording: one stranger’s line quoted as the whole, her two years set beside a four-month trial. The tell to keep: in the miracle for sale, the testimonial usually promises what the study never measured. Here the promise is skin, the trial was muscle, and the price is $99 a month.
